The introduction of multiple new pharmacological agents over the past three decades in the
field of heart failure with reduced ejection fraction (HFrEF) has led to reduced rates of …

Aims Worsening heart failure (HF) is associated with shorter left ventricular systolic ejection
time (SET), but there are limited data describing the relationship between SET and clinical …

Omecamtiv mecarbil (OM) is a myosin activator agent developed for the treatment of heart
failure. OM was reported to increase left ventricular ejection fraction and systolic ejection …

Aim N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) is predictive of both outcomes
and response to treatment in patients with heart failure with reduced ejection fraction …

Aims Colour tissue Doppler imaging (TDI) M‐mode through the mitral leaflet is an easy and
precise method to obtain cardiac time intervals including isovolumic contraction time (IVCT) …

Heart failure with reduced ejection fraction (HFrEF) is a highly morbid condition for which
exercise intolerance is a major manifestation. However, methods to assess exercise …

Background: Omecamtiv mecarbil (OM) enhances systolic function in vivo by directly binding
the myosin cross-bridges (XBs) in the sarcomere. However, the mechanistic details …

Despite recent advances in chronic heart failure management (either pharmacological or
non-pharmacological), the prognosis of heart failure (HF) patients remains poor. This poor …

Abstract Purpose of Review Cardiac myosin inhibitors (CMIs) and activators are emerging
therapies for hypertrophic cardiomyopathy (HCM) and heart failure with reduced ejection …

Over the past decade, the constant progress in science and technologies has provided
innovative drug molecules that address specific disease mechanisms thus opening the era …